Broadwood Capital Is Still Bullish On BioTime, Inc. (BTX), Further Increases Stake

Neal C. Bradsher, the manager of Broadwood Capital, is still bullish on BioTime, Inc. (NYSEMKT:BTX) and has further increased his fund’s stake in the company. According to a recent Form 4 filing with the Securities and Exchange Commission, Broadwood Capital has added 370,000 shares to its previous position in two transactions, at a price of $2.65 apiece. As a result, Broadwood’s stake surged to approximately 13.8 million BioTime, Inc. (NYSEMKT:BTX) shares, while Bradsher holds an additional 63,000 shares.


Jim Simons has also become a fan of BioTime, Inc. (NYSEMKT:BTX) and has initiated a position for his fund during the first quarter of 2014. In its latest 13F filing, Renaissance Technologies has reported ownership of 51,700 shares. Ken Griffin also sees great potential in this company and has increased his fund’s investment by 9% during the same period. Citadel Investment Group holds approximately 13,800 shares as of March 31, 2014. David E Shaw, on the other hand, has chosen to limit his fund’s exposure to BioTime, Inc. (NYSEMKT:BTX) and has cut its stake by 37% to about 49,300 shares.

Disclosure: none.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!